AI Article Synopsis
- Supraventricular tachycardia (SVT) is the most common tachyarrhythmia needing treatment in infants without heart disease, primarily caused by atrioventricular re-entry.
- Acute treatment for a single SVT episode usually has a great prognosis, but ongoing prophylactic medication is often advised during the first year of life to prevent recurrences.
- Despite the availability of effective antiarrhythmic drugs, choosing the right medication requires a careful analysis of the risks and benefits for each individual case.
Article Abstract
Supraventricular tachycardia (SVT), being atrioventricular re-entry the underlying mechanism, is the most frequent tachyarrhythmia requiring a medical treatment in infants with no cardiac disease. The acute treatment of a single episode of SVT has generally an excellent prognosis. An antiarrhythmic prophylaxis of SVT recurrences is usually recommended during the first year of life. Although many efficient drugs are available for the SVT treatment, a careful risk-benefit analysis of each single case should suggest the correct drug choice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/14767058.2010.517937 | DOI Listing |
Publication Analysis
Top Keywords
supraventricular tachycardia
8
drug choice
8
tachycardia neonates
4
neonates antiarrhythmic
4
antiarrhythmic drug
4
choice dilemma
4
dilemma supraventricular
4
svt
4
tachycardia svt
4
svt atrioventricular
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!